In an editorial in the New England Journal of Medicine, two medical device experts posit that real-world evidence (RWE) is most useful in the postmarket setting, where our current systems are inadequate for ensuring the safety and performance of medical devices. However, using RWE for initial marketing decisions for medical devices carries significant risk, as RWE analyses are observational in nature and don’t control for treatment selection bias. (Regulatory Focus)